Joachim Von Pawel
2 Robert Koch Allee
Gauting, BY 82131, Germany
Gauting, BY 82131, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications
Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations.
Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
Published: January 26, 2024
Lack of clinical utility of serum macrophage migration inhibitory factor (MIF) for monitoring therapy response and estimating prognosis in advanced lung cancer.
Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
Published: August 07, 2023
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 17, 2023
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 05, 2023
Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients.
Journal: Diagnostics (Basel, Switzerland)
Published: January 16, 2021
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 03, 2018
Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: August 31, 2018
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 29, 2018
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: April 20, 2018
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 16, 2018
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer.
Journal: Clinical lung cancer
Published: January 31, 2018
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
Journal: The oncologist
Published: November 02, 2017
Last Updated: 09/26/2026